Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia.
OBJECTIVE
To evaluate the prevalence in normal pregnancies of anti-32 glycoprotein I (anti-beta2GPI) antibodies, and their association with obstetrical complications.


METHODS
Prospective study of anti-beta2GPI and anticardiolipin (CL) antibodies in 510 healthy pregnant women at 15-18 weeks. According to the results, women were categorized into three groups: group I, negative for both antibodies; group II, positive for anti-beta2GPI antibodies; group III, positive for aCL only. The rates of fetal loss, abruptio placentae, preeclampsia-eclampsia, and fetal growth retardation were compared in the three groups.


RESULTS
Anti-beta2GPI antibodies were found in 20 women (3.9%) and aCL in 8 patients (1.6%). Obstetrical complications were more frequent, even if not significantly different, in group II, 15%, than in group I, 4.1% (difference 10.9%; 95% confidence interval (CI): 1.6-20.2%; p=0.0575), while no complications were seen in group III. Preeclampsia-eclampsia were significantly more frequent in group II (10%) than in group I (0.8%; difference 9.2%; 95% CI: 4.4-14%; p=0.021). The prevalence of fetal growth retardation was not significantly different in the two groups (5% vs. 2%, respectively).


CONCLUSIONS
Our findings indicate that anti-beta2GPI antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia, even if more conventional antiphospholipid antibodies are not present. This observation suggests that these antibodies should be investigated in such cases, in order to improve the outcome of subsequent pregnancies, as well as in women with a history of early and/or recurrent severe preeclampsia in order to start a prophylactic treatment (i.e. low-dose aspirin or heparin).
Faden
D
D
Department of Obstetrics and Gynecology, University of Brescia, Italy.
Tincani
A
A
Tanzi
P
P
Spatola
L
L
Lojacono
A
A
Tarantini
M
M
Balestrieri
G
G
D000037:Abruptio Placentae / Q000453:epidemiology / Q000276:immunology; D000328:Adult; D000906:Antibodies / Q000097:blood*; D017153:Antibodies, Anticardiolipin / Q000097:blood*; D004461:Eclampsia / Q000453:epidemiology / Q000276:immunology; D005260:Female; D005313:Fetal Death / Q000453:epidemiology / Q000276:immunology; D005317:Fetal Growth Retardation / Q000453:epidemiology / Q000276:immunology; D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D011225:Pre-Eclampsia / Q000453:epidemiology / Q000276:immunology; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000453:epidemiology*; D015995:Prevalence; D053482:beta 2-Glycoprotein I
D000906:Antibodies; D017153:Antibodies, Anticardiolipin; D006023:Glycoproteins; D053482:beta 2-Glycoprotein I